SCHEMBL1008570

SCHEMBL1008570

CCOC(=O)Cc1ccccc1OCc1c(C)cccc1C

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.51
SLC22A12 Q96S37 1/20 0.48
CFD P00746 1/20 0.45
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
PKM P14618 1/20 0.44
SGMS2 Q8NHU3 1/20 0.43
NLRP3 Q96P20 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008047 0.86 CYP4F2 (0.56) SLC22A12SGMS2NLRP3CYP4F2CYP4A11
SCHEMBL960144 0.84 SLC22A12 (0.62) SLC22A12CFDSGMS2L3MBTL1
SCHEMBL20976999 0.84 L3MBTL1 (0.59) SLC22A12CFDSGMS2L3MBTL1TDP1
SCHEMBL7890168 0.84 TBXAS1 (0.59) TBXAS1PKML3MBTL1CYP4F2CYP4A11
SCHEMBL5661211 0.83 TBXAS1 (0.53) TBXAS1CFDL3MBTL1TDP1ALDH1A1
SCHEMBL5659207 0.80 TBXAS1 (0.62) TBXAS1PKML3MBTL1CYP4F2CYP4A11
SCHEMBL30249949 0.78 PKM (0.55) TBXAS1PKMNLRP3L3MBTL1CYP4F2
SCHEMBL1107140 0.78 PKM (0.55) TBXAS1PKMNLRP3L3MBTL1CYP4F2
SCHEMBL1081012 0.78 SLC22A12 (0.74) SLC22A12PPARGPPARAPKMNLRP3
SCHEMBL27688208 0.78 TBXAS1 (0.54) TBXAS1CFDPKML3MBTL1CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 TBXAS1 2432/4885SLC22A12 139/4885CFD 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.